Patents by Inventor Adam HARTIGAN
Adam HARTIGAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230017979Abstract: The invention features compositions and methods for conditioning a patient (e.g., to facilitate transplantation and/or engraftment). The invention provides a base editing strategy targeting cell surface proteins that is useful for conditioning. In one aspect, the invention provides methods of producing a hematopoietic stem cell or progenitor thereof for the treatment of a hemoglobinopathy, hematologic cancer, or myeloproliferative disease.Type: ApplicationFiled: August 28, 2020Publication date: January 19, 2023Applicant: Beam Therapeutics Inc.Inventors: Adam HARTIGAN, Tanggis BOHNUUD
-
Publication number: 20210379195Abstract: Described herein are compositions and methods useful for the depletion of CD117+ or CD45+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. The compositions and methods described herein can be used to treat a disorder, for instance, by depleting a population of CD117+ or CD45+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for allogeneic hematopoietic stem cell transplant therapy and to improve the engraftment of allogeneic hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: ApplicationFiled: April 29, 2021Publication date: December 9, 2021Inventors: Rahul Palchaudhuri, Jennifer Lynn Proctor, Geoffrey O. Gillard, Anthony Boitano, Sharon Hyzy, Michael Cooke, Adam Hartigan
-
Publication number: 20210162063Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, ligands, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: ApplicationFiled: February 10, 2021Publication date: June 3, 2021Inventors: Andrew Nixon, Dwight Morrow, Adam Hartigan
-
Publication number: 20200376134Abstract: The invention provides compositions and methods useful for the depletion of cells, such as CD45+, CD135+, CD34+, CD90+, and/or CD110+ cells, and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, ligands, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD45+, CD135+, CD34+, CD90+, or CD110+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD45+, CD135+, CD34+, CD90+, or CD110+ cancer cells or autoimmune cells.Type: ApplicationFiled: April 20, 2020Publication date: December 3, 2020Inventors: Andrew Nixon, Dwight Morrow, Adam Hartigan
-
Publication number: 20200289664Abstract: The invention provides methods of preventing and treating graft-versus-host-disease and autoimmune diseases, such as those arising from transplant therapy, by selective depletion of hematopoietic cells through the use of antibody-drug conjugates and ligand-drug conjugates that specifically bind CD137. The compositions and methods described herein can be used to treat a variety of pathologies, including stem cell disorders and other blood conditions.Type: ApplicationFiled: January 21, 2020Publication date: September 17, 2020Inventors: Adam Hartigan, Anthony Boitano, Michael Cooke, Megan D. Hoban, Rahul Palchaudhuri
-
Patent number: 10624973Abstract: The invention provides compositions and methods useful for the depletion of cells, such as CD45+, CD135+, CD34+, CD90+, and/or CD110+ cells, and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, ligands, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD45+, CD135+, CD34+, CD90+, or CD110+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD45+, CD135+, CD34+, CD90+, or CD110+ cancer cells or autoimmune cells.Type: GrantFiled: February 28, 2019Date of Patent: April 21, 2020Assignee: Magenta Therapeutics, Inc.Inventors: Andrew Nixon, Dwight Morrow, Adam Hartigan
-
Patent number: 10576161Abstract: The invention provides methods of preventing and treating graft-versus-host-disease and autoimmune diseases, such as those arising from transplant therapy, by selective depletion of hematopoietic cells through the use of antibody-drug conjugates and ligand-drug conjugates that specifically bind CD137. The compositions and methods described herein can be used to treat a variety of pathologies, including stem cell disorders and other blood conditions.Type: GrantFiled: January 19, 2018Date of Patent: March 3, 2020Assignee: Magenta Therapeutics, Inc.Inventors: Adam Hartigan, Anthony Boitano, Michael Cooke, Megan D. Hoban, Rahul Palchaudhuri
-
Publication number: 20190328901Abstract: The invention provides compositions and methods useful for the depletion of cells, such as CD45+, CD135+, CD34+, CD90+, and/or CD110+ cells, and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, ligands, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD45+, CD135+, CD34+, CD90+, or CD110+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD45+, CD135+, CD34+, CD90+, or CD110+ cancer cells or autoimmune cells.Type: ApplicationFiled: June 19, 2017Publication date: October 31, 2019Applicant: Magenta Therapeutics, Inc.Inventors: Andrew NIXON, Dwight MORROW, Adam HARTIGAN
-
Patent number: 10434185Abstract: The invention provides methods of preventing and treating graft-versus-host-disease and autoimmune diseases, such as those arising from transplant therapy, by selective depletion of hematopoietic cells through the use of antibody-drug conjugates and ligand-drug conjugates that specifically bind CD137. The compositions and methods described herein can be used to treat a variety of pathologies, including stem cell disorders and other blood conditions.Type: GrantFiled: November 21, 2018Date of Patent: October 8, 2019Assignee: Magenta Therapeutics, Inc.Inventors: Adam Hartigan, Anthony Boitano, Michael Cooke, Megan D. Hoban, Rahul Palchaudhuri
-
Publication number: 20190192682Abstract: The invention provides compositions and methods useful for the depletion of cells, such as CD45+, CD135+, CD34+, CD90+, and/or CD110+ cells, and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, ligands, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD45+, CD135+, CD34+, CD90+, or CD110+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD45+, CD135+, CD34+, CD90+, or CD110+ cancer cells or autoimmune cells.Type: ApplicationFiled: February 28, 2019Publication date: June 27, 2019Inventors: Andrew Nixon, Dwight Morrow, Adam Hartigan
-
Publication number: 20190134217Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, ligands, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: ApplicationFiled: October 11, 2018Publication date: May 9, 2019Inventors: Andrew Nixon, Dwight Morrow, Adam Hartigan
-
Publication number: 20190076548Abstract: The invention provides methods of preventing and treating graft-versus-host-disease and autoimmune diseases, such as those arising from transplant therapy, by selective depletion of hematopoietic cells through the use of antibody-drug conjugates and ligand-drug conjugates that specifically bind CD137. The compositions and methods described herein can be used to treat a variety of pathologies, including stem cell disorders and other blood conditions.Type: ApplicationFiled: November 21, 2018Publication date: March 14, 2019Inventors: Adam Hartigan, Anthony Boitano, Michael Cooke, Megan D. Hoban, Rahul Palchaudhuri
-
Patent number: 10111966Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, ligands, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: GrantFiled: June 19, 2017Date of Patent: October 30, 2018Assignee: Magenta Therapeutics, Inc.Inventors: Andrew Nixon, Dwight Morrow, Adam Hartigan
-
Publication number: 20180289832Abstract: The invention provides methods of preventing and treating graft-versus-host-disease and autoimmune diseases, such as those arising from transplant therapy, by selective depletion of hematopoietic cells through the use of antibody-drug conjugates and ligand-drug conjugates that specifically bind CD137. The compositions and methods described herein can be used to treat a variety of pathologies, including stem cell disorders and other blood conditions.Type: ApplicationFiled: January 19, 2018Publication date: October 11, 2018Inventors: Adam Hartigan, Anthony Boitano, Michael Cooke, Megan D. Hoban, Rahul Palchaudhuri
-
Publication number: 20170360954Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, ligands, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: ApplicationFiled: June 19, 2017Publication date: December 21, 2017Inventors: Andrew NIXON, Dwight MORROW, Adam HARTIGAN